New publication where Attana technology has been applied for lead candidate selection of a new antibody-based anti-viral treatment of Hepatitis B infection
The team of prof. P. A. MacAry at the Department of Medicine, National University of Singapore has in NPJ Vaccines (npj Vaccines (2022)7:121 ) published a new paper revealing an important understanding of human immunity to Hepatitis B Virus (HBV). Their findings can potentially represent a new antibody-based anti-viral candidate for therapy for HBV infection.Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. WHO estimates that almost 300 million people were living with